In quest to leapfrog Pfizer, Peninsula vaccine company gets $85 million injection

The vaccine that halts pneumonia, meningitis and other bloodstream infections is good, but SutroVax Inc. has 85 million new reasons to believe it can do better. The Foster City company added $85 million in a Series C round and welcomed a well-respected biopharmaceutical executive as chairman as it hopes to surpass Pfizer Inc. to produce a broader, next-generation vaccine against a bacterium that causes pneumococcal disease. Thanks to the Series C found l ed by new investor TPG Growth, the five-year-old…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news